文献速递血液净化与透析肾血管病与高血压

血液透析合并房颤患者的抗凝管理:证据与观点

Anticoagulation management in haemodialysis patients with atrial fibrillation: evidence and opinion.
PubMed 文献 · Nephrol Dial Transplant · 2022-01-01

本文是一篇针对血液透析合并房颤患者抗凝管理的立场文章,汇总口服抗凝研究并给出循证结论、偏倚分析与实践建议。文章指出房颤是否为透析患者栓塞性卒中的真实危险因素尚不明确,现有CHADS₂-VASc评分截断值不能充分区分净获益与净 harm 患者,抗凝启动应比现行指南更严格;近期证据提示DOAC优于VKA,VKA尤其在高出血风险及INR不稳定患者中应避免。

要点

  • 房颤是否为透析患者栓塞性卒中的真实危险因素尚不明确。
  • 现有CHADS₂-VASc评分截断值不能充分区分净获益与净 harm 患者。
  • 抗凝启动应比现行指南更严格,VKA尤其在高出血风险及INR不稳定患者中应避免。

核心结论

  • 房颤是否为血液透析患者栓塞性卒中的真实危险因素尚不明确。
  • 现行CHADS₂-VASc评分截断值不能充分区分从口服抗凝净获益与净 harm 的透析患者。
  • 抗凝启动应比现行指南更严格,VKA在高出血风险及INR不稳定患者中尤其应避免。

研究设计与样本

  • 本文为立场文章(position paper),汇总血液透析合并房颤患者口服抗凝相关研究,并给出循证结论、偏倚来源批判性分析及基于实践的意见性建议。

主要发现

  • 近期证据显示,DOAC相对于VKA的获益-风险优势可从一般人群及中度CKD扩展至血液透析人群。
  • VKA在透析患者中可能尤其有害,应避免使用,尤其在高出血风险和INR不稳定患者中。
  • DOAC剂量探索研究提示,利伐沙班10 mg每日一次和阿哌沙班2.5 mg每日两次是透析患者的合适选择。
  • 口服抗凝药与抗血小板药联合治疗应仅限强指征并限制疗程。
  • 左心耳封堵是降低卒中风险而不增加出血倾向的潜在有吸引力方案,但尚未在透析患者中充分研究。

关键数值与推荐

  • 利伐沙班10 mg每日一次和阿哌沙班2.5 mg每日两次为透析患者的合适选择(来自DOAC剂量探索研究)。

临床怎么用

  • 抗凝启动应比现行指南更严格,并避免使用VKA,尤其在高出血风险和INR不稳定患者中。
  • 透析合并房颤患者如需DOAC,可考虑利伐沙班10 mg每日一次或阿哌沙班2.5 mg每日两次。
  • 口服抗凝药与抗血小板药联合治疗应仅限强指征并限制疗程。

局限性

  • 缺乏稳健证据指导临床决策,房颤是否为透析患者栓塞性卒中的真实危险因素尚不明确。
  • 现行CHADS₂-VASc评分截断值不能充分区分净获益与净 harm 患者。
  • 左心耳封堵尚未在透析患者中充分研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the absence of robust evidence to guide clinical decision-making, the optimal approach to prevent stroke and systemic embolism in haemodialysis (HD) patients with atrial fibrillation (AF) remains moot. In this position paper, studies on oral anticoagulation (OAC) in HD patients with AF are highlighted, followed by an evidence-based conclusion, a critical analysis to identify sources of bias and practical opinion-based suggestions on how to manage anticoagulation in this specific population. It remains unclear whether AF is a true risk factor for embolic stroke in HD. The currently employed cut-off values for the CHA2DS2-VASc score do not adequately discriminate dialysis patients deriving a net benefit from those suffering a net harm from OAC. Anticoagulation initiation should probably be more restrictive than currently advocated by official guidelines. Recent evidence reveals that the superior benefit-risk profile of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) observed in the general population and in moderate chronic kidney disease can be extended to the HD population. VKA may be especially harmful in dialysis patients and should therefore be avoided, in particular in patients with a high bleeding risk and labile international normalized ratio. Dose-finding studies of DOACs suggest that rivaroxaban 10 mg daily and apixaban 2.5 mg twice daily are appropriate choices in dialysis patients. Combined treatment with oral anticoagulants and antiplatelet agents should be reserved for strong indications and limited in time. Left atrial appendage occlusion is a potential attractive solution to reduce the risk of stroke without increasing bleeding propensity, but it has not been properly studied in dialysis patients.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. De Vriese AS, Heine G. Anticoagulation management in haemodialysis patients with atrial fibrillation: evidence and opinion. Nephrol Dial Transplant. 2022. PMID: 33647941. doi:10.1093/ndt/gfab060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。